Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 123

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 123
---
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Item 8.    Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm (PCAOB ID 238)56Consolidated Statements of Income for fiscal years 2024, 2023 and 202259Consolidated Statements of Comprehensive Income (Loss) for fiscal years 2024, 2023 and 202260Consolidated Balance Sheets as of December 28, 2024 and December 30, 202361Consolidated Statements of Cash Flows for fiscal years 2024, 2023 and 202262Consolidated Statements of Changes in Equity and Redeemable Noncontrolling Interests for fiscal years 2024, 2023 and 202263Notes to Consolidated Financial Statements64Note 1. Description of Business and Summary of Significant Accounting Policies 64Note 2. Acquisitions and Divestitures72Note 3. Revenue from Contracts with Customers75Note 4. Segment and Geographic Information77Note 5. Supplemental Cash Flow Information79Note 6. Inventory79Note 7. Property, Plant and Equipment, Net80Note 8. Venture Capital and Strategic Equity Investments80Note 9. Fair Value81Note 10. Goodwill and Intangible Assets82Note 11. Debt and Other Financing Arrangements84Note 12. Equity and Noncontrolling Interest86Note 13. Income Taxes89Note 14. Employee Benefit Plans91Note 15. Stock-based Compensation95Note 16. Restructuring and Asset Impairments97Note 17. Leases100Note 18. Commitments and Contingencies102

55

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Charles River Laboratories International, Inc.:

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Charles River Laboratories International, Inc. and its subsidiaries (the "Company") as of December 28, 2024 and December 30, 2023, and the related consolidated statements of income, of comprehensive income (loss), of changes in equity and redeemable noncontrolling interests and of cash flows for each of the three years in the period ended December 28, 2024, including the related notes (collectively referred to as the